Trial Profile

A Randomised Comparison of Daily 25 mg Versus 5 mg Lenalidomide as Maintenance Therapy After High-Dose Therapy and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Aug 2020 Results assessing efficacy and tolerability of high versus low dose lenalidomide maintenance therapy of multiple myeloma after autologous blood stem cell transplantation published in the Clinical Cancer Research
04 Dec 2018 Results assessing the Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com